Premarket Volume Scan

Market Narrative

## Premarket Scan for August 20, 2026 The clear standout this morning is MRNA, and it is not particularly close. With over 199 million shares already trading premarket and a price near $174.38, MRNA is printing the kind of volume that demands attention regardless of what caused the move. The 176.97% gap and a 12.32% premarket range confirm that this is real, committed participation, not a thin-market illusion. For context, the other gappers on today's list, including FIXX up 1413.65%, MRNX up 352.09%, and MRNY up 169.23%, are all showing zero premarket volume. Those percentage moves are meaningless without buyers and sellers behind them. MRNA has both, and that is the core thesis for today: volume is confirmation, and right now MRNA has it all to itself. The shares-only strategy is appropriate here given the vehicle designation, and the 12.32% premarket range puts this in a workable zone for structured entries rather than a chase. With no high-impact macro events on the calendar for August 20, 2026, there is no external catalyst risk that would distort price action into the open. That is actually favorable for clean technical setups on a mover like MRNA. The absence of a Fed event, CPI print, or similar headline means price discovery will be driven by the catalyst itself and order flow, not noise layered on top. For MRNA specifically, a HOD/LOD breakout strategy fits the 12.32% premarket range well. The range is meaningful but not so extended that it eliminates defined risk. Watch for consolidation in the first 5 to 15 minutes after the open, then trade the break of whichever extreme holds as support or resistance. VWAP reclaim or rejection is a secondary trigger if the open is disorderly. The rest of the list requires patience more than action. MRNX showing a 20.56% premarket range with zero volume is the clearest trap on the board today. Wide range plus no volume means the spread is doing the work, not real participants. If volume comes in on MRNX, MRNY, or FIXX after the open, reassess with fresh eyes using VWAP as the anchor strategy given those wider ranges. The volume leaders with no directional move, including MSTU, DVLT, BTCT, SNXX, and IBIT, are worth monitoring for intraday rotation or sector reads but offer no actionable premarket setup on their own. The playbook today is simple: MRNA is the only name with the volume to justify active management, and everything